KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Leases: 2020-2025

Historic Current Leases for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $11.5 million.

  • Recursion Pharmaceuticals' Current Leases rose 39.99% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 39.99%. This contributed to the annual value of $13.8 million for FY2024, which is 125.56% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Current Leases stood at $11.5 million, which was down 1.76% from $11.7 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Current Leases high stood at $13.8 million for Q4 2024, and its period low was $499,000 during Q1 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Current Leases had a median value of $8.2 million in 2024 and averaged $8.4 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Current Leases spiked by 950.50% in 2022 and then fell by 3.36% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Current Leases (Quarterly) stood at $1.4 million in 2021, then skyrocketed by 291.31% to $6.0 million in 2022, then climbed by 2.76% to $6.1 million in 2023, then surged by 125.56% to $13.8 million in 2024, then skyrocketed by 39.99% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $11.7 million for Q2 2025, and $11.9 million during Q1 2025.